PLx Pharma Hires Key Commercial Executives in Preparation for Future Launch of Aspertec
September 19 2017 - 6:50AM
PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a
late-stage specialty pharmaceutical company focused on
commercializing two patent-protected products, Aspertec™ 325 mg and
Aspertec™ 81 mg (referred to together as “Aspertec”™), today
announced the appointment of Tom Long as Vice President,
Manufacturing & Technical Operations, effective
immediately. Mr. Long will oversee ongoing manufacturing
efforts for Aspertec. Steven Valentino, will join PLx as Vice
President, Trade Sales, effective October 1, 2017. He will be
responsible for building retail trade accounts, developing retailer
and wholesaler relationships for PLx and securing distribution and
merchandising support. Concurrently Gary Mossman, Chief
Operating Officer, will transition into a senior advisory role. Mr.
Mossman will continue to actively advise the Company to ensure that
appropriate manufacturing capacity is available for Aspertec
through launch.
“Key for PLx is Tom Long’s experience in successfully
manufacturing and launching OTC products with high demand and his
experience with both New Drug Applications and OTC Monograph Drugs.
Having his expertise on hand will strengthen and support the team
as the requirements of our business expand. Steven Valentino will
be instrumental in building trade sales for PLx and positioning
Aspertec with retailers and wholesalers to maximize the launch
potential and build retail equity. We are delighted to
welcome them both to the PLx team,” stated Natasha Giordano,
President and Chief Executive Officer.
“I would like to thank Gary Mossman, who has been instrumental
in overseeing the strategy and execution of our manufacturing
plans, for his ongoing contributions and look forward to his
continued guidance,” concluded Giordano.
Most recently, Mr. Long has independently consulted in building
manufacturing and technical operations for several manufacturers
large and small. Mr. Long served as Senior Vice
President and General Manager, Manufacturing and Operations, for
Adams Respiratory Therapeutics, Inc., where he managed the overall
supply of Mucinex, Mucinex DM and Mucinex D, increasing
productivity and meeting quality objectives. For more than 17
years, he had various responsibilities including materials
management, international manufacturing, process engineering,
production planning, inventory control, materials control, quality
engineering, as well as pharmaceutical manufacturing and
packaging.
Mr. Valentino is a highly-credentialed executive with over 25
years of experience in the OTC and consumer healthcare space. His
experience includes Rx to OTC switches, brand management, trade
sales and operations and customer development across Drug, Mass
Food and Specialty. He has held positions of increasing
responsibility at Warner Lambert Consumer Health, Pfizer Consumer
Healthcare and the Johnson & Johnson Consumer Companies.
Most recently, Steven Valentino served as Vice President of
Crossmark Drug, a division of Crossmark, where he was responsible
for drug wholesale, dollar and retail merchandising for brand and
private label products.
About AspertecAspertec 325 mg is
an FDA-approved aspirin product being developed to provide
high-risk cardiovascular and stroke patients with more reliable and
predictable antiplatelet efficacy as compared to enteric-coated
aspirin, while also reducing the adverse gastric events common in
an acute setting. PLx is focused on completing manufacturing
scale-up and label finalization for Aspertec 325 mg aspirin dosage
form and preparing an sNDA for Aspertec 81 mg maintenance dose
form.
About PLx Pharma Inc.PLx Pharma
Inc. is a late-stage specialty pharmaceutical company focused
on developing its clinically validated and patent-protected
PLxGuard™ delivery system to provide safe and effective aspirin
products. The PLxGuard delivery system works by targeting delivery
of active pharmaceutical ingredients (API) to various portions of
the gastrointestinal (GI) tract. PLx believes this has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce acute GI side
effects—including erosions, ulcers and bleeding—associated with
aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline,
please visit www.plxpharma.com.
Forward-Looking StatementsAny statements made
in this press release relating to future financial or business
performance, conditions, plans, prospects, trends, or strategies
and other financial and business matters, including without
limitation, the prospects for commercializing or selling any
products or drug candidates, are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. In addition, when or if used in this press release, the words
“may,” “could,” “should,” “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “plan,” “predict” and similar expressions and
their variants, as they relate to PLx may identify forward-looking
statements. PLx cautions that these forward-looking statements are
subject to numerous assumptions, risks, and uncertainties, which
change over time. Important factors that may cause actual results
to differ materially from the results discussed in the
forward-looking statements or historical experience include risks
and uncertainties, including the failure by PLx to secure and
maintain relationships with collaborators; risks relating to
clinical trials; risks relating to the commercialization, if any,
of PLx’s proposed product candidates (such as marketing,
regulatory, product liability, supply, competition, and other
risks); dependence on the efforts of third parties; dependence on
intellectual property and risks that PLx may lack the financial
resources and access to capital to fund proposed operations.
Further information on the factors and risks that could affect
PLx’s business, financial conditions and results of operations are
contained in PLx’s filings with the U.S. Securities and
Exchange Commission (SEC), which are available
at www.sec.gov. Other risks and uncertainties are more fully
described in PLx’s prospectus supplement filed with
the SEC on June 12, 2017, and in other filings that
PLx will make going forward. The forward-looking statements
represent PLx’s estimate as of the date hereof only, and PLx
specifically disclaims any duty or obligation to update
forward-looking statements.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Source: PLx Pharma Inc.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Aug 2024 to Sep 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Sep 2023 to Sep 2024